All bills
S. 5571·119th Congress·Senate Bill

Biosimilars Access and Affordability Act

Stage not supplied

The source supplies the latest action, but no lifecycle stage.

Latest action (28 Sep 2026): Read twice and referred to the Committee on Finance.

What this bill does

This bill, S. 5571, introduced by Senator Marsha Blackburn, aims to change the rules for when biosimilar drugs can be included in price negotiations for the Medicare program. Biosimilar drugs are approved by the Food and Drug Administration (FDA) and are similar to existing biologic drugs, often offering a lower-cost alternative. The bill specifically addresses the timing of when these biosimilar products become eligible for negotiation under Medicare.

The specific details of how this bill would alter the eligibility timeline for biosimilar price negotiations are not yet available, as the full text of the bill has not been published. However, it would affect the Medicare program by potentially changing the conditions under which certain prescription drugs could have their prices negotiated, impacting both the cost of these medications and the options available to beneficiaries.

Currently, S. 5571 has just been introduced in the Senate. As an introduced bill, it has not yet undergone any committee review or floor debate. For it to potentially become law, it would need to pass both the Senate and the House of Representatives in identical form and then be signed by the President.

Plain-English summary generated by Bill100 AI from the official record. Always verify against the source below.

Timeline

  1. 28 Sep 2026

    Read twice and referred to the Committee on Finance.

Common questions

What does S. 5571 do?
This bill, S. 5571, introduced by Senator Marsha Blackburn, aims to change the rules for when biosimilar drugs can be included in price negotiations for the Medicare program. Biosimilar drugs are approved by the Food and Drug Administration (FDA) and are similar to existing biologic drugs, often offering a lower-cost alternative. The bill specifically addresses the timing of when these biosimilar products become eligible for negotiation under Medicare. The specific details of how this bill would alter the eligibility timeline for biosimilar price negotiations are not yet available, as the full text of the bill has not been published. However, it would affect the Medicare program by potentially changing the conditions under which certain prescription drugs could have their prices negotiated, impacting both the cost of these medications and the options available to beneficiaries. Currently, S. 5571 has just been introduced in the Senate. As an introduced bill, it has not yet undergone any committee review or floor debate. For it to potentially become law, it would need to pass both the Senate and the House of Representatives in identical form and then be signed by the President.
Has S. 5571 become law?
The source does not supply a confirmed lifecycle stage for S. 5571. Check the latest action and official source below.
Who sponsored S. 5571?
S. 5571 was sponsored by Sen. Blackburn, Marsha [R-TN] (R-TN), with 3 cosponsors.
What's the latest action on S. 5571?
Read twice and referred to the Committee on Finance. (28 Sep 2026).

Related bills in Health

More bills from Sen. Blackburn, Marsha [R-TN]

Bill100 mirrors the public U.S. legislative record from Congress.gov and GovTrack and adds plain-English AI summaries. It is an information tool, not legal, compliance or lobbying advice, and it is not affiliated with the U.S. Congress or any government agency. AI summaries can simplify or omit detail — every bill links to the official source; verify there before you rely on it.